PE Anti-CD39 antibody [EPR20461],Abcam,AB317885

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human

Application

Antibody Labelling, Target Binding Affinity, IHC-P

Conjugate

PE

Platform ID

BAB859210583

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NamePE Anti-CD39 antibody [EPR20461]
Cat. No.AB317885
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationPE
ApplicationAntibody Labelling, Target Binding Affinity, IHC-P
ClonalityMonoclonal
Clone NumberEPR20461
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Catalyzes the hydrolysis of nucleoside triphosphates (NTPs) and diphosphates (NDPs) (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). The enzyme sequentially removes phosphate groups in two successive steps, converting NTPs to nucleoside monophosphates (NMPs) via NDP intermediates (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). This activity contributes to the regulation of extracellular levels of nucleotides (Probable) (PubMed : 8529670, PubMed : 8626624, PubMed : 8955160, PubMed : 8996251). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow (PubMed : 8955160, PubMed : 8996251). See full target information ENTPD1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.